GC Therapeutics
Nailia Mukhamedshina is currently working as an Associate Scientist I at GC Therapeutics. Prior to this, Nailia held positions at ElevateBio and Harvard Stem Cell Institute, gaining experience in CRISPR gene editing, stem cell culture, and biology. Nailia also worked at Tufts University as a Research Assistant, specializing in diabetic foot ulcer pathogenesis and tissue engineering. Nailia's internship at Boston University involved studying Amyloidosis pathogenesis and gaining practical lab experience. Nailia holds a Doctor of Medicine (M.D.) degree from The Russian State Medical University.
GC Therapeutics
1 followers
GC Therapeutics Inc. (GCTx) uses synthetic biology to program patient-derived stem cells into any cell type with best-in-class efficiency (up to 10X), speed (up to 100X) and scalability. We dictate cells fates in a single step and have validated cells for many applications. We have also developed SuperCells™ by tailoring cells for specific diseases. The core technology of GCTx was conceived, invented and perfected in Professor George Church’s lab at Harvard Medical School. We are a group of passionate biologists and tissue engineers whose goal is to bring this breakthrough approach to patients.